Asset Details
Do you wish to reserve the book?
The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy
Do you wish to request the book?
The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy
2018
Overview
Data in support of the safety of biologic use during pregnancy continues to grow. Utilizing a national French database with linkage between mothers and children, Luu et al. demonstrated that anti-tumor necrosis factor (anti-TNF) therapy exposure did not increase infection risk in children, though the mothers had higher rates of infection. Stopping therapy prior to 24 weeks gestation led to a higher rate of disease flares in the mother with no benefit to the infant compared to continued therapy.
Publisher
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subject
